Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 14/20 | 0.52 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16703440 | 0.86 | HTR6 (0.44) | HTR6HTR2AHTR7PDPK1HTT | |
| SCHEMBL17120392 | 0.83 | HTR6 (0.49) | HTR6HTR2AHTR7PDPK1MEN1 | |
| SCHEMBL16703642 | 0.83 | HTR6 (0.52) | HTR6HTR2AHTR7HTTCYP3A4 | |
| Hydrochloric Acid SCHEMBL17097132 | 0.83 | HTR6 (0.49) | HTR6HTR2AHTR7PDPK1MEN1 | |
| SCHEMBL16703404 | 0.82 | HTR6 (0.53) | HTR6CHRNB2CHRNA4CYP3A4 | |
| Hydrochloric Acid SCHEMBL16697723 | 0.81 | HTR6 (0.52) | HTR6CHRNB2CHRNA4CYP3A4 | |
| SCHEMBL16698341 | 0.81 | HTR6 (0.45) | HTR6HTR2AHTR7PDPK1CYP3A4 | |
| SCHEMBL16698273 | 0.76 | HTR6 (0.51) | HTR6HTR2APDPK1CYP3A4HTR2C | |
| SCHEMBL16703414 | 0.75 | HTR6 (0.49) | HTR6HTR2AHTR7PDPK1 | |
| SCHEMBL17121970 | 0.75 | HTR6 (0.49) | HTR6HTR2ACYP3A4HTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160263087-A1 | NOVEL 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | ITEOS THERAPEUTICS (BE) | 2016-09-15 | — | — | US | disclosed |
| EP-3066090-A1 | 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | iTeos Therapeutics (BE) | 2016-09-14 | — | — | EP | disclosed |
| WO-2015067782-A1 | 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | ITEOS THERAPEUTICS (BE) | 2015-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160263087-A1 | NOVEL 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TDO2, IDO1, TPH1 | HTR6 84/4885CHRNB2 931/4885CHRNA4 1039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.